October 23, 2013
1 min read

Novartis reports 4% increase in third-quarter net sales

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Novartis International reported an increase in net sales for the third quarter, according to a news release.

Net sales totaled $14.3 billion, a 4% increase over the third quarter 2012. Net sales for the first 9 months of 2013 totaled $42.8 billion, a 2% increase over the first 9 months of 2012.

Net income for the third quarter totaled $2.26 billion, down 6% from the same period in 2012. The decrease was attributed to a negative currency impact.

Core operating income was down 5% from the third quarter of 2012. The decrease resulted from the impact of generic erosion, increased investment in multiple pipeline projects and high cost of goods sold over a low prior-year base, the release said.

Pharmaceutical net sales totaled $7.9 billion, a 1% increase over third quarter 2012. The increase was driven by a 10% growth in volume and a 1% increase in pricing offset by generic competition.

Alcon net sales totaled $2.5 billion, a 3% increase over third quarter 2012. The increase resulted from growth in the surgical franchise, especially in the cataract and LenSx femtosecond laser lines. Ophthalmic pharmaceuticals were up 3% from 2012, and vision care was up 1%.

Alcon operating income was $251 million, down 30% from third quarter 2012. This was attributed to higher integration costs, restructuring and incremental amortization charges.